Publication:
CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma

cris.lastimport.scopus2025-05-13T22:28:27Z
cris.virtual.departmentInternal Medicine-NTUHen_US
cris.virtual.departmentIntegrated Diagnostics and Therapeutics-NTUHen_US
cris.virtual.departmentInternal Medicineen_US
cris.virtual.departmentInternal Medicine-NTUHen_US
cris.virtual.departmentInternal Medicineen_US
cris.virtual.departmentInternal Medicine-NTUHen_US
cris.virtual.departmentSurgeryen_US
cris.virtual.departmentSurgery-NTUHen_US
cris.virtual.orcid0000-0001-5362-6953en_US
cris.virtual.orcid0000-0002-1940-6428en_US
cris.virtual.orcid0000-0002-7741-9315en_US
cris.virtual.orcid0000-0002-9126-2705en_US
cris.virtualsource.departmentd2618654-bcef-45ed-a769-5d8fd79b7d8b
cris.virtualsource.departmentd2618654-bcef-45ed-a769-5d8fd79b7d8b
cris.virtualsource.department245f5ece-4692-4d90-bfcf-2100572a15b4
cris.virtualsource.department245f5ece-4692-4d90-bfcf-2100572a15b4
cris.virtualsource.department7dd0d294-2cc0-4667-8d11-7779e9d665ea
cris.virtualsource.department7dd0d294-2cc0-4667-8d11-7779e9d665ea
cris.virtualsource.department5d536cc7-19c7-4971-ab87-9e742976239e
cris.virtualsource.department5d536cc7-19c7-4971-ab87-9e742976239e
cris.virtualsource.orcidd2618654-bcef-45ed-a769-5d8fd79b7d8b
cris.virtualsource.orcid245f5ece-4692-4d90-bfcf-2100572a15b4
cris.virtualsource.orcid7dd0d294-2cc0-4667-8d11-7779e9d665ea
cris.virtualsource.orcid5d536cc7-19c7-4971-ab87-9e742976239e
dc.contributor.authorWEI-CHIH LIAOen_US
dc.contributor.authorHSIU-PO WANGen_US
dc.contributor.authorHuang H.-Y.en_US
dc.contributor.authorMING-SHIANG WUen_US
dc.contributor.authorChiang H.en_US
dc.contributor.authorYU-WEN TIENen_US
dc.contributor.authorLin Y.-L.en_US
dc.contributor.authorLin J.-T.en_US
dc.creatorLiao W.-C.;Wang H.-P.;Huang H.-Y.;Wu M.-S.;Chiang H.;Yu-Wen Tien;Lin Y.-L.;Lin J.-T.
dc.date.accessioned2020-02-20T06:53:13Z
dc.date.available2020-02-20T06:53:13Z
dc.date.issued2012
dc.description.abstractOBJECTIVES: Liver metastasis develops in 60% of patients after resection of pancreatic adenocarcinoma (PAC) and carries a dismal prognosis, but factors predictive of liver recurrence are poorly understood. Experimental evidence suggests that liver metastasis of PAC is mediated by CXCL12/CXCR4 signaling and can be inhibited by CXCR4 antagonist. We aimed to verify whether CXCR4 expression predicts early liver recurrence and poor survival after resection, and to explore the usefulness of CXCR4 status for prognosis prediction. METHODS: Ninety-seven consecutive PAC patients undergoing R0 resection were analyzed. CXCR4 expression was analyzed by immunohistochemistry, and its associations with liver recurrence-free survival and overall survival were analyzed by Kaplan- Meier estimates and multivariable Cox and accelerated failure time regression models. RESULTS: CXCR4-positive patients had a worse prognosis than CXCR4-negative patients, with a shorter liver recurrence-free survival (median: 8.7 vs. 39.7 months; P=0.004) and overall survival (median: 10.2 vs. 22.3 months; P<0.001). Overall survival for CXCR4-positive stage IIa patients was similar to that for stage IIb patients and significantly shorter than that for CXCR4- negative stage IIa patients (median: 9.7 vs. 27.4 months; P=0.002). CXCR4 positivity was significantly associated with liver recurrence (adjusted hazard ratio 2.22, 95% confidence interval (CI) 1.15-4.30; P=0.018) and predicted a 46% (95% CI 9-68%) and 35% (95% CI 7-54%) reduction in liver recurrence-free survival and overall survival, respectively. CONCLUSIONS: Tumor CXCR4 expression independently predicts early liver recurrence and poor overall survival after resection of PAC. CXCR4 status stratifies stage IIa patients into two groups with a striking difference in prognosis. Clinical and Translational Gastroenterology (2012) 3, e22; doi:10.1038/ctg.2012.18; published online 13 September 2012 Subject Category: Liver. ? 2012 the American College of Gastroenterology.
dc.identifier.doi10.1038/ctg.2012.18
dc.identifier.issn2155-384X
dc.identifier.scopus2-s2.0-84866056928
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84866056928&doi=10.1038%2fctg.2012.18&partnerID=40&md5=429c090ae4ef2aa89f91e51d14bd6a70
dc.identifier.urihttps://scholars.lib.ntu.edu.tw/handle/123456789/461866
dc.relation.ispartofClinical and Translational Gastroenterology
dc.relation.journalvolume3
dc.subject.classification[SDGs]SDG3
dc.subject.otherchemokine receptor CXCR4; stromal cell derived factor 1; adult; article; cancer chemotherapy; cancer patient; cancer prognosis; cancer recurrence; cancer staging; cancer surgery; cancer survival; controlled study; disease association; enzyme activity; female; human; human tissue; liver metastasis; major clinical study; male; outcome assessment; overall survival; pancreas adenocarcinoma; pancreas surgery; pancreaticoduodenectomy; pancreatosplenectomy; prediction; priority journal; protein analysis; protein expression; protein function; recurrence free survival
dc.titleCXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinomaen_US
dc.typejournal articleen
dspace.entity.typePublication

Files